MCH ANALYSIS RESEARCHMain site ↗
Health Care

Health Care Supplies

7 companies under coverage.

Coverage

Health Care Supplies


Equity Research

Dentsply Sirona Inc (XRAY)

BUY. 12-month probability-weighted target $15 (+67% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

XRAYEquity ResearchMonte Carlo
12 October 2026Rating: BUY · Fair value vs price +36.1%
Equity Research

Align Technology Inc (ALGN)

BUY. 12-month probability-weighted target $167 (+17% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

ALGNEquity ResearchMonte Carlo
12 October 2026Rating: BUY · Fair value vs price +30.2%
Equity Research

The Cooper Companies, Inc (COO)

BUY. 12-month probability-weighted target $69 (+27% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

COOEquity ResearchMonte Carlo
12 October 2026Rating: BUY · Fair value vs price +24.7%
Equity Research

Envista Holdings Corp (NVST)

HOLD. 12-month probability-weighted target $26 (+12% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

NVSTEquity ResearchMonte Carlo
12 October 2026Rating: HOLD · Fair value vs price +0.4%
Equity Research

Lantheus Holdings Inc (LNTH)

HOLD. 12-month probability-weighted target $104 (+4% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

LNTHEquity ResearchMonte Carlo
12 October 2026Rating: HOLD · Fair value vs price -1.3%
Equity Research

West Pharmaceutical Services Inc (WST)

HOLD. 12-month probability-weighted target $338 (-8% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

WSTEquity ResearchMonte Carlo
12 October 2026Rating: HOLD · Fair value vs price -20.6%
Equity Research

Haemonetics Corporation (HAE)

SELL. 12-month probability-weighted target $78 (-34% vs spot). P/E Multiple explains 59% of Monte Carlo outcome variance.

HAEEquity ResearchMonte Carlo
12 October 2026Rating: SELL · Fair value vs price -38.7%
MCH ANALYSIS · All research · Research, not personal financial advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.20.0 · US-listed

MCH Analysis is a general investment-research publication of MCH Advisory (Pty) Ltd. It is not personal financial advice and does not take your circumstances into account. MCH is not a licensed financial services provider or a registered investment adviser. Past performance, whether actual or simulated, does not predict future results. Subscriber Agreement | Privacy and Cookie Notice | Research Governance Policies